|Bid||132.50 x 800|
|Ask||0.00 x 800|
|Day's range||134.09 - 138.59|
|52-week range||113.36 - 174.16|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||8.25|
|Earnings date||03 Feb 2022|
|Forward dividend & yield||2.48 (1.79%)|
|Ex-dividend date||18 Jan 2022|
|1y target est||168.40|
Quest Diagnostics (DGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.
Adults across the country can now access comprehensive virtual preventive care without visiting a doctor's office through the new Comprehensive Health Profile from QuestDirect™ the consumer-initiated testing platform from Quest Diagnostics (NYSE: DGX). This new offering evaluates more than 100 health-related data points -- combining access to the same laboratory tests doctors order, a behavioral health risk assessment and biometric measurements, such as weight and blood pressure, to give individ